Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Laura is the vice president of content for 

) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

Articles

The former television personality and heart surgeon was confirmed in a 53-45 vote on party lines.

Dr Oz Confirmed by the Senate Along Party Lines to Lead CMS

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease (IgG4-RD), a chronic and debilitating immune-mediated inflammatory condition.

Inebilizumab FDA Approved as First Treatment for IgG4-RD

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

The West Health-Gallup Healthcare Indices Study indicates that approximately 29 million people are unable to afford or access quality healthcare, the highest since 2021.

11% of Americans Cannot Access Quality Health Care, Survey Finds

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

New findings may help patients with low to moderate risk of tumor lysis syndrome while reducing the burden for hematologists.

Pharmacist-Led Model Reduces Tumor Lysis Risk in CLL Venetoclax Therapy

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Guilio Cossu, MD, FMedSci, FEAS, is currently a Professor of Regenerative Medicine at the University of Manchester. His wealth of research expertise encompasses regenerative medicine, cell therapies, muscular dystrophy, and developmental biology. 

One of the major highlights of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference is that invaluable networking opportunities can help clinicians elevate their own best practices. 

Building Community and Advancing Care at MDA 2025

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established. 

Data Gaps Leave Long-Term Impact of Ex Vivo Gene Therapy in DMD Uncertain